ArticleCellular oncology (Dordrecht, Netherlands)2026
RBM15/IGF2BP2-PTPRH m6A regulatory axis in non-small cell lung cancer.
Article in Cellular oncology (Dordrecht, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-small cell lung cancer (NSCLC) remains a leading cause of cancer-related death globally, highlighting the urgent need for new molecular drivers and therapeutic targets. This study investigates the role of protein tyrosine phosphatase receptor type H (PTPRH) and its regulation through an epitranscriptomic mechanism in NSCLC.
methodsWe performed an integrated analysis of datasets from The Cancer Genome Atlas and Gene Expression Omnibus to evaluate PTPRH expression and its prognostic significance. PTPRH levels were further validated in clinical NSCLC specimens and correlated with clinicopathological features. We assessed the functional consequences of PTPRH expression on proliferation, apoptosis, migration, invasion, and angiogenesis using in vitro and in vivo models. The underlying mechanism involving N6-methyladenosine (m6A) modification was explored by examining the roles of the m6A writer RBM15 and the reader IGF2BP2 on PTPRH transcript stability. Gain- and loss-of-function experiments, coupled with rescue studies, were conducted to delineate the functional axis.
resultsPTPRH was significantly overexpressed in NSCLC tissues, and its elevated expression correlated with poor patient prognosis. Functionally, PTPRH promoted tumor cell proliferation, migration, invasion, and xenograft tumor growth, while simultaneously inhibiting apoptosis and enhancing angiogenesis via the VEGF pathway. Mechanistically, PTPRH expression was post-transcriptionally stabilized by m6A methylation. RBM15 facilitated m6A deposition on PTPRH transcripts, while IGF2BP2 binding to these modified sites enhanced PTPRH mRNA stability. Depletion of RBM15 or IGF2BP2 reduced PTPRH levels and suppressed malignant behaviors, whereas their overexpression produced the opposite effects. The oncogenic functions of PTPRH were confirmed to be dependent on this regulatory axis.
conclusionOur study unveils a novel epigenetic regulatory axis in which RBM15-mediated m6A modification and IGF2BP2-dependent recognition stabilize PTPRH mRNA, thereby promoting NSCLC progression. This work expands the understanding of post-transcriptional regulation in lung cancer and identifies the RBM15/IGF2BP2-PTPRH axis as a potential therapeutic target for NSCLC intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.